NATIONAL INSTITUTE ON DRUG ABUSE POLICY ON COUNSELING AND TESTING FOR HIV/AIDS
AND OTHER INFECTIOUS DISEASES
Release Date: January 4, 2001
NOTICE: NOT-DA-01-001
National Institute on Drug Abuse
(http://www.nih.gov)
PURPOSE
In 1995, the National Institute on Drug Abuse (NIDA) established a
policy intended to reduce drug abuse-related transmission of HIV in its
study populations. The policy encouraged NIDA-funded researchers to
make HIV-risk reduction counseling and testing available to subjects at
high risk for acquiring or transmitting HIV. In recognition of
concerns about other infectious agents and their linkages with both
drug abuse and HIV, this Notice revises the 1995 policy (available at
http://grants.nih.gov/grants/guide/notice-files/not95-154.html) to
include hepatitis B (HBV), hepatitis C (HCV), tuberculosis, sexually
transmitted diseases (STDs), and other infectious agents in addition to
HIV. NIDA’s policy is that NIDA-funded researchers are strongly
encouraged to provide and/or refer research subjects to HIV risk
reduction counseling and testing, treatment, and other appropriate
interventions, as needed, to prevent acquisition and transmission of
infectious agents.
A number of blood-borne and sexually transmitted infections (e.g., HBV,
HCV, and both ulcerative and nonulcerative STDs) continue to cause
major health problems among injecting and noninjecting drug users and
their sex partners in the United States and internationally. The
infants and children of drug users and their sex partners are also at
high risk of exposure to these agents through vertical transmission
from an infected mother, with consequent development of disease. Air-
borne transmission of tuberculosis, including multiple-drug resistant
strains, has also increased among drug abusers and their sex partners,
posing a significant threat to public health. However, a variety of
scientifically-based approaches, including testing and counseling,
behavioral interventions, and disease and drug addiction treatment, are
now available to facilitate risk reduction, behavior change, and health
among drug users and their sexual partners and families.
As a public health research institute, NIDA believes that researchers
share the responsibility for preventing the acquisition and
transmission of drug abuse-related diseases and helping individuals to
find treatment for drug abuse and its comorbid conditions. Researchers
funded by NIDA to conduct research in community outreach settings,
clinics, hospitals, drug treatment programs, or other clinical settings
and who have contact with clients at risk for acquisition or
transmission of HIV and other blood-borne and sexually transmitted
infections are strongly encouraged to provide education, counseling,
and information on how to obtain treatment to those clients. Education
and counseling to clients at risk should include offering testing for
HIV, HBV, and HCV, and screening for STDs, if these services are
available on site. Referrals to testing, screening, and treatment
services should be offered if they are not available at the on-site
location.
In general, the opportunity to offer education and counseling will
occur in any clinical or laboratory study that provides diagnostic,
treatment, or other health or social services to participants over a
period of time. Easy-to-read materials on drug abuse, HIV/AIDS, and
other comorbid and infectious conditions should also be available to
study participants in such research settings as surveys and studies
where investigator-subject contacts occur only once and are brief.
Counseling materials developed by NIDA (www.nida.nih.gov) and materials
developed by the Centers for Disease Control and Prevention (CDC)
(www.cdc.gov) are available for use by interested parties, grantees,
and contractors. Appropriate educational materials (manuals,
brochures, and posters) may also be obtained by calling or writing the
National Clearinghouse for Alcohol and Drug Information (1-800-729-
6686) and the CDC’s National Prevention Information Network (1-800-458-
5231).
For additional information on this policy, contact
Henry L. Francis, M.D. or Elizabeth Y. Lambert, M.Sc.
Center on AIDS and Other Medical Consequences of Drug Abuse
National Institute on Drug Abuse
6001 Executive Blvd.
Room 5198 MSC 9593
Bethesda, MD 20892
Telephone: (301) 443-2104 or (301) 402-1933
E-mail: hfrancis@nida.nih.gov or elambert@nida.nih.gov
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
|
|
|
Department of Health and Human Services (HHS)
|
|
|
|
NIH... Turning Discovery Into Health®
|